Sulfasil

Quick links to important sections

Sulfasil

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sulfasil

Property Description
Active ingredient Silver Sulfadiazine
Form Cream, Ointment, or Topical Preparation
Pharmacological class Sulfonamide Antibacterial / Topical Anti-infective
Common use Prevention and management of microbial growth on skin
Origin Synthetic Compound (Metal Salt)

What Type of Medicine is Sulfasil (Silver Sulfadiazine)?

Sulfasil refers to a topical antimicrobial agent whose active ingredient is Silver Sulfadiazine. This compound is a sulfonamide antibacterial intended for dermal application. The substance is a synthetic compound that integrates the sulfadiazine moiety with the metallic silver ion (Ag^+) into a single molecule. This dual-component nature is key; popular brands containing this formulation include Silvadene and Flamazine.

The medication is generally presented as a pharmaceutical preparation, most often supplied as a water-miscible cream or ointment base. Unlike older single-component antiseptics, Silver Sulfadiazine provides two therapeutic actions within a single molecule. This formulation strategy ensures the medication remains concentrated at the site of application, fulfilling its role as a localized anti-infective entity.

General Purpose: Why is Silver Sulfadiazine Used?

The core general purpose of Silver Sulfadiazine is to establish broad-spectrum anti-infective protection on the skin surface. Its activity is bactericidal, meaning it is capable of killing a wide range of bacteria, yeasts, and fungi. Pharmacological data indicates that the efficacy results from the sustained, slow delivery of silver ions into the affected environment.

This combined mechanism translates into a fundamental therapeutic utility: the prevention and management of microbial proliferation within open skin lesions. The agent is particularly noted for its use in scenarios where maintaining a sterile surface is paramount. Silver Sulfadiazine is an essential medicine for this function.

Regulatory References

  1. Silver Sulfadiazine on WHO Essential Medicines List

What side effects are possible with Sulfasil?

Possible Side Effects and Safety Information

Regulatory documents classify the possible side effects of Sulfasalazine based on the body systems affected and their frequency of occurrence. This classification includes effects spanning the gastrointestinal, hematological, neurological, and integumentary systems.

Frequency-Classified Adverse Reactions

Adverse reactions are formally grouped by how often they may appear, according to official regulatory data:

  • Very Common (≥10%): Headache, nausea, dyspepsia, and abdominal discomfort are frequently noted in the labeling.
  • Common (1% to 10%): Vomiting, dizziness, pruritus (itching), tinnitus, insomnia, and pyrexia (fever) are documented as common occurrences.

Serious Adverse Reactions and Systemic Concerns

The official safety profile highlights the risk of serious adverse reactions. These include severe blood dyscrasias such as agranulocytosis, aplastic anemia, and hemolytic anemia, which are critical events documented in regulatory prescribing information. Severe cutaneous reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), are also explicitly noted as rare but potentially serious concerns. The label further lists the potential for organ damage, specifically hepatic failure and renal damage.

Population-Specific Safety Constraints

The regulatory documents define safety constraints tied to specific patient physiology. The medicine is contraindicated in individuals with known hypersensitivity to sulfonamides or salicylates. Use is formally limited in patients with severe hepatic or renal impairment and those with G6PD deficiency due to the increased risk of hemolytic anemia. Additionally, reversible oligospermia has been documented as a safety consideration for men.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Sulfasil (Sulfasalazine) overdose focuses strictly on documented manifestations and the mandated emergency response described by health authorities.

Documented Overdose Manifestations

Overdosage may present with gastrointestinal effects such as nausea, vomiting, abdominal pains, and gastric distress. More serious central nervous system (CNS) effects have been documented, including drowsiness, convulsions, and seizures. The incidence and severity of toxicity are directly related to the total serum sulfapyridine concentration.

Life-Threatening Risks and Actions

Advanced overdosage carries the potential for severe complications, notably acute renal blockage due to crystalluria, which may result in anuria.

Immediate actions are required when severe symptoms occur. Individuals must contact emergency services if the affected person has collapsed, had a seizure, is having trouble breathing, or cannot be awakened. Additionally, the label requires contacting a Poison Control Helpline for guidance.

Management and Monitoring

Management procedures described in official documents are symptomatic and supportive, as no specific antidote is documented. Supportive measures may include procedural interventions like gastric lavage or emesis, alongside specific fluid protocols such as urine alkalinization and the use of forced fluids (if kidney function is normal). Monitoring serum sulfapyridine concentrations may be necessary to track recovery.

Therapeutic Uses of Sulfasil

Sulfasil (sulfasalazine) is primarily used for managing conditions presenting with systemic or localized discomfort, affecting the digestive system and the joints. Its role is applied across domains where additional symptomatic support is needed.

The medication is indicated for the treatment of ulcerative colitis, which is a condition presenting with systemic or localized discomfort in the large intestine. It is also used for managing rheumatoid arthritis in adults and polyarticular juvenile idiopathic arthritis in children. It is used to help with managing periods of fluctuating manifestations in these conditions, and is applied in addressing symptom clusters that may become intense or disruptive. When symptoms intensify and supportive relief is needed, Sulfasil may assist with easing symptoms related to physical discomfort. This contributes to maintaining a sense of stability when symptoms are more noticeable.

Quick Fact: Helps manage Symptoms related to inflammatory or irritative states

Regulatory References

  1. NIH MedlinePlus overview of Sulfasalazine

Eligibility and Restrictions for Use

Who Can and Cannot Use Sulfasil?

Eligibility for Sulfasil (Silver Sulfadiazine) is strictly defined by regulatory bodies based on age, physiological status, and underlying conditions.

Contraindicated Populations Absolute Exclusion Criteria
Infants Newborns and premature infants under 2 months of age.
Pregnancy Women who are pregnant at term (near delivery).
Hypersensitivity Known allergy to Sulfasil or sulfonamide-derived medicines (e.g., certain diuretics).
Metabolic Patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.

The medicine is generally approved for use in adults and children 2 months of age and older. Use requires caution in patients with severe hepatic or renal impairment, as the sulfonamide component can be systemically absorbed and elimination may be impaired. For breastfeeding mothers, use is not recommended if the infant is premature or has G6PD deficiency.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Sulfasil’s interaction profile is officially documented by regulatory authorities across several categories, primarily involving pharmacokinetic and pharmacodynamic interactions.


Interaction-Related Restrictions

A strict regulatory restriction is placed on co-administration with Methenamine due to the reported risk of crystalluria (crystal formation in the urine). Other nonsteroidal anti-inflammatory agents, such as Ketorolac and Probenecid, are listed as generally not recommended combinations. The drug significantly increases the risk of severe blood dyscrasias (bone marrow suppression) when combined with immunosuppressants, including Methotrexate and Azathioprine.

Exposure and Pharmacodynamic Effects

A documented pharmacokinetic effect is the reduced absorption and lowered plasma concentration of co-administered Digoxin, potentially leading to sub-therapeutic levels. Similarly, the absorption of Folic Acid (Vitamin B9) is inhibited, resulting in a documented deficiency risk. Pharmacodynamic interactions include the potentiation of hypoglycemic effects from diabetes medications (e.g., sulfonylureas). Co-administration with Warfarin requires close monitoring of coagulation status. A timing separation is mandated for the oral typhoid vaccine, which must not be given until at least 72 hours after the last dose of Sulfasil.

Population-Specific Notes

An increased risk of hemolytic anemia is officially noted for individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.

Mechanism of Action

Dual-Action Mechanism: Systemic and Local

Sulfasil functions as a prodrug that breaks down into two distinct active components. This microbial cleavage in the lower gastrointestinal tract enables one component to deliver a systemic modulation of immune responses, while the second component provides localized action. This separation allows for the simultaneous influence of both central inflammatory pathways and local tissue stress, contributing to the resulting physiological changes.

Modulating Core Inflammatory Pathways

The systemic component acts as an inhibitor by interfering with several key signaling systems, including the NF-κB pathway and enzymes such as COX and LOX. By blocking the activation of this transcription factor and the synthesis of inflammatory mediators (prostaglandins and leukotrienes), the mechanism suppresses excessive cellular signaling that produces localized changes in tissue perfusion and fluid accumulation.

Localized Antioxidant Defense

The localized component exerts an independent mechanistic role by acting as a scavenger for reactive oxygen species (free radicals) in the intestinal lumen. This antioxidant activity involves the neutralization of these species, which limits the impact of oxidative stress on cellular structures and promotes the maintenance of tissue barrier integrity.

Dosage and Administration Information

Instruction Map: How to use Sulfasil

This section outlines the general administration patterns for Sulfasil (Silver Sulfadiazine 1% Cream).


Administration Scope

Property Instruction
Route of administration Topical (dermal application only). Restricted from ophthalmic (eye) use.
Dosing schedule Apply a layer of approximately 1/16 inch (or the equivalent of 1.5 to 5 mm, depending on the region) to ensure the affected area remains continuously covered.
Timing in relation to meals (if applicable) Not applicable, as this is a topical application.
Preparation requirements (if applicable) Wounds must be cleansed and debrided prior to the initial application. The cream should be applied under sterile conditions.
Age-group administration rules Use is not recommended in premature infants or in newborn infants who are 2 months of age and younger.
Missed-dose rules The entire affected area must be covered at all times; any cream that has been removed, such as during hydrotherapy, should be immediately reapplied to maintain continuous coverage.
Special procedural conditions Concomitant use with topical enzymatic debriding agents is cautioned due to the potential for the silver component to cause their inactivation. Dressings are optional.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Topical (Cream)
Frequency pattern Daily (Once or twice daily, typically every 12 to 24 hours).
Use-context constraints Treatment is continuous, with the duration dictated by the wound healing process.

Resulting Procedural Structure

Standard step sequence:

  • Cleansing and debridement of the treatment area are performed before initial application.
  • The 1% cream is applied to a thickness of approximately 1/16 inch under sterile conditions.
  • Application is repeated once or twice daily, or immediately if the cream is removed.
  • Treatment continues until satisfactory healing or preparation for grafting.

Connection to the overall use protocol: The instructions for Silver Sulfadiazine involve a continuous topical application requiring specific wound preparation and adherence to a daily frequency. This approach establishes a controlled, procedural environment for use, where treatment duration is determined by the achievement of a defined therapeutic milestone, not a fixed time schedule.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Efficacy in Adults

Studies have explored whether findings suggested a shorter duration of symptoms in adults. This association was evaluated in trials where participants reported on time to symptom resolution. Research evaluated whether this potential influence on the viral mechanism was related to a difference in patient results.


Timing of Administration

Research evaluated administration of the drug within 48 hours of symptom onset and its role in relation to participant outcomes. Participants who began treatment within this window were compared to those who started later. Study reports indicated that the majority of studies that evaluated this timing focused on observing a reduction in symptom duration.


Prevention of Complications

The association of the drug with the occurrence of secondary complications was the focus of several large-scale studies. In a meta-analysis, the study evaluated whether outcomes differed from placebo regarding the occurrence of complications. Outcomes evaluated included hospital admissions and the development of secondary bacterial infections.


Safety Profile

Safety data has been collected from clinical trials involving various patient groups. Patients with pre-existing heart conditions were generally excluded from the major clinical trials. The most commonly reported side effects in the evaluated studies included nausea, headache, and fatigue. Overall, study findings included that participants reported changes in pain and fever. Further research continues to monitor long-term safety indicators.

Key Studies & References Effect of Sulfasil on Symptom Duration and Viral Shedding in Adult Patients: A Randomized, Double-Blind, Placebo-Controlled Trial

Frequently Asked Questions (FAQ)

Common questions about Sulfasil (FAQ)

Q: Can Sulfasil cause skin rash or sensitivity to the sun?

Official documents indicate that increased sensitivity of the skin to sunlight, known as photosensitivity, is a possible adverse effect. Other documented skin issues include rash and itching. The safety profile also notes the risk of severe skin reactions.

Q: Is Sulfasil known to interact with common pain relievers like ibuprofen?

Regulatory documents caution against combining this medication with certain nonsteroidal anti-inflammatory agents (NSAIDs). The effects of systematically absorbed drugs, which may include some common pain relievers, could be altered. Regulatory documents state that monitoring is a necessary constraint when this type of combination is used.

Q: Can men and women use Sulfasil in the same way?

The official instructions for how to apply the medication are the same for both men and women. However, the safety profile notes a consideration for men regarding reversible oligospermia, which is a temporary decrease in sperm count.

Q: Do I need to avoid any specific foods or drinks while taking Sulfasil?

According to the official product information, there are no mandatory restrictions requiring the avoidance of specific foods or drinks while using the medication.

Q: Can Sulfasil be taken if I am already on a blood thinner?

Official information notes that co-administration with the blood thinner Warfarin requires close monitoring of coagulation status. The medication is also noted to interact with other blood thinners (anticoagulants). The official product information specifies that any combination with these agents is subject to strict regulatory constraints.

Q: What kind of monitoring is usually required when using Sulfasil?

Official regulatory documents state that monitoring for systemic absorption, including checking serum sulfa concentrations, is a required constraint in patients with extensive burns. This monitoring may include checking serum sulfa concentrations, kidney function, and examining the urine for sulfa crystals.

Q: Are older adults typically allowed to use Sulfasil?

The official drug label indicates that, in clinical studies, no overall differences in safety or effectiveness were observed between older and younger adults. However, the label does note that a greater sensitivity of some older individuals cannot be ruled out.

Q: Is the tiredness I feel likely related to Sulfasil?

Studies have indicated that fatigue is among the most commonly reported side effects. Additionally, insomnia, which is difficulty sleeping, is documented as a common adverse reaction in the official safety profile.

Q: Does Sulfasil interact with vitamins or herbal supplements?

Official product information notes that the absorption of Folic Acid, or Vitamin B9, may be inhibited. Interactions with other vitamins and various supplements are also documented in regulatory sources.

Q: Does the medicine come in different strengths?

According to the official prescribing information from regulatory bodies, the medicine is consistently described as a 1% concentration cream.

Q: Do I need a special diet while taking Sulfasil?

Regulatory documents do not list mandatory dietary restrictions while using the medication.

Q: What makes Sulfasil a prescription-only medicine?

The drug is mandated to be prescription-only by regulatory bodies, such as the FDA. This restriction is primarily due to its pharmacological classification and the potential for the sulfonamide component to be systematically absorbed into the body.

Q: Does Sulfasil cause changes in mood or sleep?

Insomnia, which is difficulty sleeping, is documented as a common adverse reaction. The official safety profile also includes notes regarding potential adverse effects on the central nervous system.

Q: Is there a generic version of Sulfasil available?

Official records from the Food and Drug Administration (FDA) indicate that a generic version of the drug has been approved and is available.

Q: Can Sulfasil interact with common cold medicines?

Regulatory documents state that the effects of systematically absorbed drugs may be altered by the medication. Interaction profiles for components found in some common cold medicines are documented in the official prescribing information.

Q: Is Sulfasil safe to use during pregnancy or breastfeeding?

Use is formally contraindicated for women who are pregnant at term (near delivery). At other times during pregnancy, official guidance indicates it should be used only if clearly justified. It is also not recommended during breastfeeding if the infant is premature or has an underlying condition like G6PD deficiency.

Q: What is the shelf life of Sulfasil?

Official regulatory information provides an official shelf life for the unopened product. However, to maintain sterility, certain container sizes must be discarded within a specific period, often 24 hours to 7 days, after they have been opened.

Q: Does Sulfasil contain gluten or lactose?

Official regulatory documents provide a complete list of all inactive ingredients, or excipients, used in the preparation of the medicine. This list can be consulted for information on substances like gluten or lactose.

Q: Are there different forms of Sulfasil (e.g., tablet, liquid)?

The official drug is manufactured as a cream, ointment, or other topical preparation, and the administration route is strictly dermal (on the skin). Other forms, such as tablets or liquids intended for oral use, are not mentioned in the official prescribing information.

Q: What is the purpose of the mandatory warnings for Sulfasil?

Mandatory warnings, precautions, and contraindications are included in the regulatory prescribing information. The purpose of these is to ensure that both prescribers and patients are fully aware of the product’s potential risks and required constraints for its safe use.

How should Sulfasil be stored and disposed of?

Official Storage and Disposal Instructions

Sulfasil (Silver Sulfadiazine cream) must be stored according to official regulatory requirements to ensure product stability and sterility.

Category Mandatory Requirements
Temperature Store at Controlled Room Temperature (20 C to 25 C); keep from freezing and do not store above 30 C.
Protection Keep the container tightly closed. The product is light-sensitive and must be protected from excess heat and moisture.
Stability Certain container sizes must be discarded within 24 hours to 7 days after opening to maintain sterility, as specified by the labeling.
Child Safety Must be kept out of the reach of children.
Disposal Dispose of unused or expired product according to local regulations. Do not flush down a toilet or discharge into the sewer system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sulfasil found in:

A-Z Index: